MOLECULAR DYNAMICS STUDIES OF FULL HUMAN MATRIX METALLOPROTEINASE 9 LIGANDED WITH N-HYDROXY-2-[(4-PHENYLPHENYL) SULFONYL-PROPAN-2-YLOXYAMINO] ACETAMIDE

Roy Gunawan Wicaksono; Maywan Hariono; Enade Perdana Istyastono

doi:10.24071/jpsc.001970

MOLECULAR DYNAMICS STUDIES OF FULL HUMAN MATRIX METALLOPROTEINASE 9 LIGANDED WITH N-HYDROXY-2-[(4-PHENYLPHENYL) SULFONYL-PROPAN-2-YLOXYAMINO] ACETAMIDE

Roy Gunawan Wicaksono⁽¹⁾, Maywan Hariono⁽²⁾, Enade Perdana Istyastono^(3*),

(1) Faculty of Pharmacy, Sanata Dharma University, Yogyakarta
(2) Faculty of Pharmacy, Sanata Dharma University, Yogyakarta
(3) Faculty of Pharmacy, Sanata Dharma University, Yogyakarta
(*) Corresponding Author

Abstract

The research presented in this article aimed to provide a full quarternary structure of human matrix metalloproteinase 9 (MMP9) enzyme with a ligand in the catalytic site for structure-based virtual screening. The enzyme plays an important role in wound healing of diabetic foot ulcer. By employing the primary structure of the enzyme obtained from UniProt database (UniProt:P14780), the theoretical structure of full apoenzyme of the human MMP9 (PDB:1LKG), the crystal structures of the catalytic domain (PDB:4H3X) and the hemopexin domain (PDB:1ITV) of the human MMP9, homology modeling studies have been performed. The ligand N-2-(biphenyl-4-yl-sulfonyl)-N-2-(isopropyloxy)-acetohydroxamic acid (CC27) or N-hydroxy-2-[(4-phenylphenyl)sulfonyl-propan-2-yloxyamino]acetamide (IUPAC version) from PDB:4H3X was embedded in the catalytic site of the enzyme. The modeling made use of the modules of homology modeling in YASARA structure. Subsequently, molecular dynamics (MD) simulations in YASARA structure were performed to examine the stability of the enzyme. The homology model was found stable after 5.05 ns and the lowest energy of the model was found at the 6.40 ns of the MD production run. This lowest energy snapshot was then energetically minimized and analyzed for its applicability for virtual screening. This optimized model was then stored in Mendeley Data (DOI: 10.17632/4gsb4p75gz.1).

Keywords

homology modeling; matrix metalloproteinase 9; molecular dynamics simulations; virtual screening; YASARA structure.

Full Text:

PDF

References

Alford, V.M., Kamath, A., Ren, X., Kumar, K., Gan, Q., Awwa, M., Tong, M., Seeliger, M.A., Cao, J., Ojima, I., Sampson, N.S., 2017. Targeting the hemopexin-like domain of latent matrix metalloproteinase-9 (proMMP-9) with a small molecule inhibitor prevents the formation of focal adhesion junctions. ACS Chem. Biol., 12 (11), 27882803.

Ayuk, S.M., Abrahamse, H., Houreld, N.N., 2016. The role of matrix metalloproteinases in diabetic wound healing in relation to photobiomodulation. J. Diabetes Res., 2016 (2897656), 1-9.

Cavasotto, C.N., Phatak, S.S., 2009. Homology modeling in drug discovery: Current trends and applications. Drug Discov. Today, 14 (13-14), 676-683.

Delozier, T.C., Kissling, G.E., Coulter, S.J., Dai, D., Foley, J.F., Alyce, J., Murphy, E., Steenbergen, C., Zeldin, D.C., Goldstein, J.A., 2011. Small molecule anti-cancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9 (MMP-9). Cancer Res., 71 (14), 49774988.

Dufour, A., Cao, J., Kuscu, C., Dufour, A., Zucker, S., Sampson, N.S., 2010. Role of matrix metalloproteinase-9 dimers in cell migration. J. Biol. Chem., 285 (46), 3594435956.

Ezhilarasan, R., Jadhav, U., Mohanam, I., Rao, J.S., Gujrati, M., Mohanam, S., 2009. The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int. J. Cancer, 124 (2), 306315.

Hariono, M., Yuliani, S.H., Istyastono, E.P., Riswanto, F.D.O., Adhipandito, C.F., 2018. Matrix metalloproteinase 9 (MMP9) in wound healing of diabetic foot ulcer: Molecular target and structure-based drug design. Wound Medicine, 22 (September 2018), 113.

Jones, I., Nguyen, T.T., Peng, Z., Chang, M., 2019. Targeting MMP-9 in diabetic foot ulcers. Pharmaceuticals, 12 (2), 79.

Krieger, E., Koraimann, G., Vriend, G., 2002. Increasing the precision of comparative models with YASARANOVA- A self-parameterizing force field. Proteins, 47 (3), 393402.

Krieger, E., Vriend, G., 2015. New ways to boost molecular dynamics simulations. J. Comput. Chem., 36 (13), 9961007.

Liu, K., Watanabe, E., Kokubo, H., 2017. Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. J. Comput. Aided Mol. Des., 31, 201211.

Mart-Renom, M.A., Stuart, A.C., Roberto, S., Melo, F., Andrej, S., 2000. Comparative protein structure modeling

of genes and genomes. Ann. Rev. Biophys. Biomol. Struct., 29, 291325.

Prasasty, V.D., Istyastono, E.P., 2019. Structure-based design and molecular dynamics simulations of pentapeptide AEYTR as a potential acetylcholinesterase inhibitor. Indones. J. Chem., in press, 17.

Roeb, E., Schleinkofer, K., Kernebeck, T., Ptsch, S., Jansen, B., Behrmann, I., Matern, S., Grtzinger, J., 2002. The matrix metalloproteinase 9 (MMP-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J. Biol. Chem., 277 (52), 5032650332.

Vandooren, J., Knoops, S., Buzzo, J.L.A., Boon, L., Martens, E., Opdenakker, G., Kolaczkowska, E., 2017. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS ONE, 12 (4), 119.

Wang, X., Song, K., Li, L., Chen, L., 2018. Structure-based drug design strategies and challenges. Curr. Top. Med. Chem., 18 (12), 9981006.

DOI: https://doi.org/10.24071/jpsc.001970